After treatment with propagermanium, the serum IL‐6, which participated in tumour angiogenesis, was downregulated in a dose‐dependent manner, suggesting that propagermanium may have the potential to inhibit angiogenesis and prevent cancer metastasis. The gene discussed is IL6; the disease is neoplasm.